4-((S)-2-Benzyloxycarbonylamino-3-hydroxy-3-methoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester | 195877-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((S)-2-Benzyloxycarbonylamino-3-hydroxy-3-methoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester
• CAS: 195877-57-7
• 化学式: C₂₃H₃₄N₂O₇
• 分子量: 450.532
• InChiKey: RVOSIMIVHGAOMF-OYKVQYDMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.85
• 重原子数：
  32.0
• 可旋转键数：
  7.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  114.4
• 氢给体数：
  2.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  4-((S)-2-Benzyloxycarbonylamino-3-hydroxy-3-methoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 以100%的产率得到
  参考文献：
  名称：

  Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety

  摘要：

  2-Amino-3-piperidin-4-yl-propionic acid containing peptidomimetics are potent protease inhibitors when combined with an appropriate keto-thiazole or keto-carboxylic acid moiety. A novel P-1 residue in factor Xa and thrombin inhibitors has been found resulting in IC50 values as low as 0.048 mu M, a factor of ten more potent than Argatroban. Starting with non-chiral synthetic routes, a new stereospecific route was developed as well as a new solid-phase method. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00179-1
• 作为产物：
  描述：

  S-2-azido-3-(N-Boc-piperidyl)-propionic acid 在 palladium on activated charcoal 盐酸 、 二碳酸二叔丁酯 、 苄基三乙基氯化铵 、 氢气 、 二异丁基氢化铝 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-((S)-2-Benzyloxycarbonylamino-3-hydroxy-3-methoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety

  摘要：

  2-Amino-3-piperidin-4-yl-propionic acid containing peptidomimetics are potent protease inhibitors when combined with an appropriate keto-thiazole or keto-carboxylic acid moiety. A novel P-1 residue in factor Xa and thrombin inhibitors has been found resulting in IC50 values as low as 0.048 mu M, a factor of ten more potent than Argatroban. Starting with non-chiral synthetic routes, a new stereospecific route was developed as well as a new solid-phase method. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00179-1